CVS Health Reports Strong Q1 Performance with Increased Revenues and EPS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 39 minutes ago
0mins
Should l Buy CVS?
Source: PRnewswire
- Significant Revenue Growth: CVS Health reported total revenues of $100.426 billion for Q1 2026, an increase of $5.838 billion from $94.588 billion in Q1 2025, demonstrating strong performance in the health services sector and reinforcing its market position.
- Earnings Per Share Increase: The company achieved a diluted EPS of $2.30 for the first quarter, up from $1.41 in the previous year, reflecting ongoing improvements in the health insurance business and enhanced operational efficiency.
- Robust Cash Flow: Operating cash flow for the first quarter was $4.2 billion, down from $4.6 billion year-over-year, yet the company maintains an optimistic outlook for full-year cash flow, projecting at least $9.5 billion, indicating strong financial health.
- Strong Performance in Health Insurance: The Health Care Benefits segment generated total revenues of $35.971 billion, an increase of $1.161 billion year-over-year, with medical membership at 26 million and a medical benefit ratio (MBR) declining to 84.6%, showcasing effective cost control and service quality enhancement strategies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 82.010
Low
91.00
Averages
96.71
High
105.00
Current: 82.010
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. The Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and, through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVS Health Q1 Earnings Preview: Focus on Stabilization
- Earnings Expectations: CVS Health is set to report Q1 earnings on May 6, with consensus estimates predicting an EPS of $2.21, down 1.8% year-over-year, and revenue of $95.02 billion, up 0.4% year-over-year, indicating modest top-line growth but ongoing profitability pressures.
- Estimate Revisions: Recent revisions show 6 upward and 11 downward adjustments for EPS, and 4 upward versus 8 downward for revenue, reflecting increased uncertainty regarding near-term performance, although CVS has historically beaten estimates 75% of the time over the past two years.
- Operational Optimization: CVS's Aetna insurance unit plans to align 5-10 prior authorization categories with cross-payer standards by 2026, representing about 40% of volume, aimed at enhancing operational efficiency and improving cost control.
- Policy Environment Impact: Proposed healthcare reforms by the Trump administration could reshape the insurance landscape, while a 2.48% increase in Medicare Advantage payments for 2027 offers some margin support, albeit at a slower pace than previous years; CVS expects adjusted EPS for 2026 to be between $7.00 and $7.20, aligning with market expectations.
See More
CVS Health Reports Strong Earnings and Revenue Growth
- Earnings Highlights: CVS Health reported a non-GAAP EPS of $2.57, exceeding expectations by $0.36, which underscores the company's robust profitability and boosts investor confidence in its future growth prospects.
- Revenue Growth: The company achieved total revenue of $100.4 billion, surpassing market expectations by $5.38 billion, reflecting strong market demand in the healthcare sector and effective cost control strategies.
- Cost Trend Focus: Investors are closely monitoring CVS's cost trends and margin changes, as the company continues to optimize operational efficiency, which is expected to further enhance profitability and strengthen market competitiveness.
- Dividend Security: Supported by solid fundamentals, CVS Health continues to offer secure dividend returns, attracting income-seeking investors and enhancing its appeal as a diversified income investment.
See More
CVS Health Raises Full-Year Outlook After Strong Q1 Earnings
- Earnings Beat: CVS Health reported Q1 2026 revenue of $100.4 billion, reflecting approximately 6% year-over-year growth, with its Health Care Benefits segment contributing $36 billion, leading to an upward revision of its full-year adjusted EPS outlook to $7.30-$7.50, surpassing analysts' expectations of $7.16.
- Health Benefits Growth: The Health Care Benefits segment achieved $3 billion in adjusted operating income, marking a ~53% year-over-year increase, primarily driven by strong performance in its Government business, despite ongoing macroeconomic pressures and rising cost trends.
- Membership Decline Impact: Despite strong overall performance, CVS's medical membership fell by approximately 600,000 to 26 million at the quarter's end, largely due to the company's decision to exit the individual exchange market in 2026, which may negatively impact future revenues.
- Pharmacy Services Performance: CVS's Health Services segment, which includes Caremark, contributed $48.2 billion in revenue, reflecting an ~11% year-over-year growth, while revenue from its Pharmacy & Consumer Wellness segment remained steady at $32 billion, demonstrating the company's ongoing efforts to diversify its revenue streams.
See More
CVS Q1 Earnings Beat Expectations, Raises 2026 Guidance
- Earnings Beat: CVS reported a Q1 non-GAAP EPS of $2.57, exceeding expectations by $0.36, indicating strong operational performance that boosts investor confidence.
- Revenue Growth: The company achieved revenues of $100.4 billion, a 6.1% year-over-year increase, surpassing market expectations by $5.38 billion, which reinforces its competitive position in the market.
- Guidance Upgrade: CVS raised its 2026 GAAP diluted EPS guidance range to $6.24 to $6.44 from $5.94 to $6.14, and adjusted EPS guidance to $7.30 to $7.50 from $7.00 to $7.20, reflecting confidence in future performance.
- Cash Flow Outlook: The company anticipates cash flow from operations to reach at least $9.5 billion, up from a previous estimate of $9.0 billion, indicating improved financial health that supports future investments and shareholder returns.
See More
CVS Surpasses Q1 Earnings Estimates, Raises 2026 Guidance
- Earnings Beat: CVS reported adjusted earnings per share of $2.57 for Q1, exceeding the expected $2.20, indicating significant progress in its turnaround strategy, with 2026 EPS guidance raised to $7.30-$7.50 from $7.00-$7.20.
- Significant Revenue Growth: The company achieved total revenue of $100.43 billion in Q1, a 6.2% increase year-over-year, surpassing analyst expectations of $95.09 billion, reflecting strong performance across all business segments, particularly in insurance, with 2026 revenue projected to reach at least $405 billion.
- Insurance Business Improvement: CVS's insurance segment generated $35.97 billion in revenue during Q1, up approximately 3% from the previous year and exceeding the $33.28 billion expected by analysts, showcasing Aetna's enhanced operational efficiency and better management of medical costs.
- Effective Cost Control: The company has successfully cut $2 billion in costs during its transformation, optimizing store performance and leadership structure, while the medical benefit ratio improved from 87.3% to 84.6%, indicating enhanced profitability and operational efficiency.
See More
CVS Health Reports Strong Q1 Performance with Increased Revenues and EPS
- Significant Revenue Growth: CVS Health reported total revenues of $100.426 billion for Q1 2026, an increase of $5.838 billion from $94.588 billion in Q1 2025, demonstrating strong performance in the health services sector and reinforcing its market position.
- Earnings Per Share Increase: The company achieved a diluted EPS of $2.30 for the first quarter, up from $1.41 in the previous year, reflecting ongoing improvements in the health insurance business and enhanced operational efficiency.
- Robust Cash Flow: Operating cash flow for the first quarter was $4.2 billion, down from $4.6 billion year-over-year, yet the company maintains an optimistic outlook for full-year cash flow, projecting at least $9.5 billion, indicating strong financial health.
- Strong Performance in Health Insurance: The Health Care Benefits segment generated total revenues of $35.971 billion, an increase of $1.161 billion year-over-year, with medical membership at 26 million and a medical benefit ratio (MBR) declining to 84.6%, showcasing effective cost control and service quality enhancement strategies.
See More
CVS Health Q1 Earnings Preview: Focus on Stabilization
- Earnings Expectations: CVS Health is set to report Q1 earnings on May 6, with consensus estimates predicting an EPS of $2.21, down 1.8% year-over-year, and revenue of $95.02 billion, up 0.4% year-over-year, indicating modest top-line growth but ongoing profitability pressures.
- Estimate Revisions: Recent revisions show 6 upward and 11 downward adjustments for EPS, and 4 upward versus 8 downward for revenue, reflecting increased uncertainty regarding near-term performance, although CVS has historically beaten estimates 75% of the time over the past two years.
- Operational Optimization: CVS's Aetna insurance unit plans to align 5-10 prior authorization categories with cross-payer standards by 2026, representing about 40% of volume, aimed at enhancing operational efficiency and improving cost control.
- Policy Environment Impact: Proposed healthcare reforms by the Trump administration could reshape the insurance landscape, while a 2.48% increase in Medicare Advantage payments for 2027 offers some margin support, albeit at a slower pace than previous years; CVS expects adjusted EPS for 2026 to be between $7.00 and $7.20, aligning with market expectations.
See More
CVS Health Reports Strong Earnings and Revenue Growth
- Earnings Highlights: CVS Health reported a non-GAAP EPS of $2.57, exceeding expectations by $0.36, which underscores the company's robust profitability and boosts investor confidence in its future growth prospects.
- Revenue Growth: The company achieved total revenue of $100.4 billion, surpassing market expectations by $5.38 billion, reflecting strong market demand in the healthcare sector and effective cost control strategies.
- Cost Trend Focus: Investors are closely monitoring CVS's cost trends and margin changes, as the company continues to optimize operational efficiency, which is expected to further enhance profitability and strengthen market competitiveness.
- Dividend Security: Supported by solid fundamentals, CVS Health continues to offer secure dividend returns, attracting income-seeking investors and enhancing its appeal as a diversified income investment.
See More
CVS Health Raises Full-Year Outlook After Strong Q1 Earnings
- Earnings Beat: CVS Health reported Q1 2026 revenue of $100.4 billion, reflecting approximately 6% year-over-year growth, with its Health Care Benefits segment contributing $36 billion, leading to an upward revision of its full-year adjusted EPS outlook to $7.30-$7.50, surpassing analysts' expectations of $7.16.
- Health Benefits Growth: The Health Care Benefits segment achieved $3 billion in adjusted operating income, marking a ~53% year-over-year increase, primarily driven by strong performance in its Government business, despite ongoing macroeconomic pressures and rising cost trends.
- Membership Decline Impact: Despite strong overall performance, CVS's medical membership fell by approximately 600,000 to 26 million at the quarter's end, largely due to the company's decision to exit the individual exchange market in 2026, which may negatively impact future revenues.
- Pharmacy Services Performance: CVS's Health Services segment, which includes Caremark, contributed $48.2 billion in revenue, reflecting an ~11% year-over-year growth, while revenue from its Pharmacy & Consumer Wellness segment remained steady at $32 billion, demonstrating the company's ongoing efforts to diversify its revenue streams.
See More
CVS Q1 Earnings Beat Expectations, Raises 2026 Guidance
- Earnings Beat: CVS reported a Q1 non-GAAP EPS of $2.57, exceeding expectations by $0.36, indicating strong operational performance that boosts investor confidence.
- Revenue Growth: The company achieved revenues of $100.4 billion, a 6.1% year-over-year increase, surpassing market expectations by $5.38 billion, which reinforces its competitive position in the market.
- Guidance Upgrade: CVS raised its 2026 GAAP diluted EPS guidance range to $6.24 to $6.44 from $5.94 to $6.14, and adjusted EPS guidance to $7.30 to $7.50 from $7.00 to $7.20, reflecting confidence in future performance.
- Cash Flow Outlook: The company anticipates cash flow from operations to reach at least $9.5 billion, up from a previous estimate of $9.0 billion, indicating improved financial health that supports future investments and shareholder returns.
See More
CVS Surpasses Q1 Earnings Estimates, Raises 2026 Guidance
- Earnings Beat: CVS reported adjusted earnings per share of $2.57 for Q1, exceeding the expected $2.20, indicating significant progress in its turnaround strategy, with 2026 EPS guidance raised to $7.30-$7.50 from $7.00-$7.20.
- Significant Revenue Growth: The company achieved total revenue of $100.43 billion in Q1, a 6.2% increase year-over-year, surpassing analyst expectations of $95.09 billion, reflecting strong performance across all business segments, particularly in insurance, with 2026 revenue projected to reach at least $405 billion.
- Insurance Business Improvement: CVS's insurance segment generated $35.97 billion in revenue during Q1, up approximately 3% from the previous year and exceeding the $33.28 billion expected by analysts, showcasing Aetna's enhanced operational efficiency and better management of medical costs.
- Effective Cost Control: The company has successfully cut $2 billion in costs during its transformation, optimizing store performance and leadership structure, while the medical benefit ratio improved from 87.3% to 84.6%, indicating enhanced profitability and operational efficiency.
See More
CVS Health Reports Strong Q1 Performance with Increased Revenues and EPS
- Significant Revenue Growth: CVS Health reported total revenues of $100.426 billion for Q1 2026, an increase of $5.838 billion from $94.588 billion in Q1 2025, demonstrating strong performance in the health services sector and reinforcing its market position.
- Earnings Per Share Increase: The company achieved a diluted EPS of $2.30 for the first quarter, up from $1.41 in the previous year, reflecting ongoing improvements in the health insurance business and enhanced operational efficiency.
- Robust Cash Flow: Operating cash flow for the first quarter was $4.2 billion, down from $4.6 billion year-over-year, yet the company maintains an optimistic outlook for full-year cash flow, projecting at least $9.5 billion, indicating strong financial health.
- Strong Performance in Health Insurance: The Health Care Benefits segment generated total revenues of $35.971 billion, an increase of $1.161 billion year-over-year, with medical membership at 26 million and a medical benefit ratio (MBR) declining to 84.6%, showcasing effective cost control and service quality enhancement strategies.
See More
